Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study.

cancer chemotherapy gemcitabine platinum compounds venous thromboembolism

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
03 Sep 2020
Historique:
received: 15 07 2020
revised: 28 08 2020
accepted: 01 09 2020
entrez: 9 9 2020
pubmed: 10 9 2020
medline: 10 9 2020
Statut: epublish

Résumé

Gemcitabine and platinum-based agents could increase the risk of venous thromboembolism (VTE) in patients with cancer. We evaluated the additive predictive utility of these agents towards cancer-associated VTE beyond a recently developed and externally validated clinical prediction model, which was based on tumor entity and continuous D-dimer levels. Analysis was performed in the derivation cohort of this model, obtained from the Vienna Cancer and Thrombosis Study (CATS), a prospective observational cohort study (

Identifiants

pubmed: 32899157
pii: cancers12092493
doi: 10.3390/cancers12092493
pmc: PMC7564761
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : Austrian Science Fund
ID : Special Research Program (SFB) 54
Organisme : Oesterreichische Nationalbank
ID : 17828

Références

Cancer Sci. 2008 Feb;99(2):391-7
pubmed: 18271937
J Clin Oncol. 2011 Sep 1;29(25):3466-73
pubmed: 21810688
Br J Clin Pharmacol. 2013 Sep;76(3):338-47
pubmed: 23834355
Blood. 2008 Oct 1;112(7):2703-8
pubmed: 18539899
J Clin Oncol. 2012 Nov 1;30(31):3870-5
pubmed: 23008313
Circulation. 2016 Mar 29;133(13):1272-89
pubmed: 27022039
J Thromb Thrombolysis. 2019 Jul;48(1):125-133
pubmed: 30919253
Cell Mol Life Sci. 2019 Feb;76(4):681-697
pubmed: 30382284
Lancet Haematol. 2018 Jul;5(7):e289-e298
pubmed: 29885940
Expert Opin Drug Saf. 2008 Nov;7(6):703-16
pubmed: 18983217
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Thromb Haemost. 2017 Jan 26;117(2):219-230
pubmed: 27882374
Haematologica. 2017 Sep;102(9):1494-1501
pubmed: 28550192
J Clin Oncol. 2012 Dec 10;30(35):4416-26
pubmed: 23150697
J Thromb Haemost. 2015 Mar;13(3):390-7
pubmed: 25529107
Jpn J Cancer Res. 1998 Jul;89(7):757-67
pubmed: 9738983
Intern Emerg Med. 2012 Jun;7(3):291-2
pubmed: 22547369
J Clin Oncol. 2009 Sep 1;27(25):4124-9
pubmed: 19636003
N Engl J Med. 2013 Oct 31;369(18):1691-703
pubmed: 24131140

Auteurs

Florian Moik (F)

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.

Nick van Es (N)

Department of Vascular Medicine, Amsterdam Academic Medical Center, 1105 Amsterdam, The Netherlands.

Florian Posch (F)

Division of Oncology, Department of Internal Medicine, Comprehensive Cancer Center Graz, Medical University of Graz, 8036 Graz, Austria.

Marcello Di Nisio (M)

Department of Medicine and Ageing Sciences, University G. D'Annunzio, 66100 Chieti, Italy.

Thorsten Fuereder (T)

Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.

Matthias Preusser (M)

Clinical Division of Oncology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.

Ingrid Pabinger (I)

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.

Cihan Ay (C)

Clinical Division of Haematology and Haemostaseology, Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, 1090 Vienna, Austria.
I. M. Sechenov First Moscow State Medical University, 119146 Moscow, Russia.

Classifications MeSH